MERCK KGAA |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.31 USD | -1.55% |
|
-6.65% | +4.31% |
| 05:51am | Chemical industry wage partners seek solution before the end of the peace period | DP |
| 06-25 | German Stocks Fall Tuesday | DJ |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With a 2024 P/E ratio at 22.91 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 3.51 times its current sales, is high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +4.31% | 73.29B | - | ||
| +17.03% | 9.11B | A- | ||
| -23.31% | 4.44B | A- | ||
| +15.70% | 4.24B | B- | ||
| +32.83% | 4.03B | - | ||
| +9.37% | 2.14B | B | ||
| +9.30% | 1.94B | - | - | |
| -33.37% | 1.9B | C- | ||
| -0.50% | 1.64B | - | - | |
| -46.20% | 1.63B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MRK Stock
- MKKGY Stock
- Ratings Merck KGaA
